Replies to post #2658 on Skye Bioscience Inc (SKYE)

[Vinpat]

Not surprising. The success of their IPO was almost entirely CEO driven. The indications they've targeted are very risky. The Nemus group expected this and these results is one of the reasons why I maintain Nemus has the most valuable IP and have chosen indications with the best likelihood of success.

Zyne got as high as $40 when it first came out. SMH.

[cjarmstrong]

Unfortunate, but reiterates the importance of risk assessment.